• contact BIO

    brought to you by
    Biotechnology Industry Organization
    1201 Maryland Ave., SW
    Washington, DC 20024
    202.962.9200
    www.bio.org

    terms of use
    privacy policy
  • Categories

  • Twitter Updates

BIO Applauds New NIH Grants

The National Institutes of Health unveiled two new grant programs this week for small research companies that will be supported by stimulus funds provided to the NIH under the American Recovery & Reinvestment Act of 2009.  “These new programs will help provide much-needed resources to biotech companies, who are at the cusp of many medical [...]

Google to get into the biotech biz

The economic news this week wasn’t all doom and gloom – Google announced Google Ventures, a new venture capital fund that will finance biotechnology start ups, among other things.

According to Google Blog:

At its core, Google Ventures is charged with finding and helping to develop exceptional start-ups. We’ll be focusing on early stage investments across [...]

SBIR Can Be Key to Accessing Financing in a Troubled Economy

With Congress knee-deep in legislation to help stimulate the economy and arguing over the budget, things are starting to heat up for Small Business Innovation Research (SBIR) as well. The current credit crunch has made obtaining funding for biomedical research even tougher. Researchers are facing unprecedented challenges. Unfortunately for some in biotech, slow cash flow [...]

Massachusetts Understands SBIR Benefits

Massachusetts, a state with a large emerging biotechnology company sector, continues to discuss the Small Business Innovation Research Program and who is in and who is out. With the current state of the economy, the U.S. should be working harder than ever to form successful public/private partnerships that will encourage growth and stability in the [...]

Kansas City craves innovation

Stories are appearing nationally that highlight the importance of SBIR funding in partnership with venture capital dollars on local economies. These investment capital/government funding partnerships can foster growth in the biotech industry. This is the best way to ensure that our scientists are able to develop cutting-edge treatments and therapies and bring them to the [...]

Who Benefits from SBIR

In St. Louis, another small biotech firm is contemplating what steps to take if the SBIR bill is not renewed soon. Currently, Kereos Inc., a 15-employee company studying promising new methods of detecting and treating cancer is excluded from the SBIR program. This piece in Sunday’s St. Louis Post Dispatch illustrates the struggles that many [...]

Senate Small Business Committee Passes an SBIR bill

The Senate Small Business Committee has passed an SBIR reauthorization bill. We hope the House and Senate will work together to pass a final reauthorization bill before this program is set to expire on September 30, 2008.
From the Puget Sound Business Journal:

Under a compromise negotiated in the U.S. Senate, small companies that are majority-owned [...]

Huffington Post and SBIR

Lloyd Chapman wrote his perception of SBIR’s passage out of Senate Committee. However, he misses a few key points.
The bill passed by the Senate Committee on Small Business and Entrepreneurship is a constructive step forward in restoring SBIR eligibility for small biotechnology companies. It takes into account, to a degree, the fact that biotech [...]

More from Maryland

Both Forbes and East Coast Blogging mentions that people can now apply for the $6 million in biotechnology tax credits in Maryland. They didn’t discuss how enthusiastic the Maryland Biotech community is over this new plan.

There is a lot of growing excitement over Governor O’Malley’s BIO 2020 Initiative. Today, the Baltimore [...]

Biotechnology, a Massachusetts Force

Recently, there was an interesting study conducted by PricewaterhouseCoopers, the New England Healthcare Institute, the Massachusetts Life Sciences Center, Xconomy and the Massachusetts Technology Collaborative on the Massachusetts Life Sciences Super Cluster, showing the value of a strong science sector economically.   This Super Cluster includes Universities, teaching hospitals, biotechnology, medical device, and pharmaceutical companies.  Software, [...]